The following is a summary of the BioCardia, Inc. (BCDA) Q1 2024 Earnings Call Transcript:
Financial Performance:
BioCardia reported $55,000 revenue for Q1 2024, similar to Q1 2023's revenue.
The company reduced expenses significantly by 35% compared to the previous quarter, thanks to decreased research and development costs and selling, general and administrative expenses.
BioCardia managed to lower the net loss for Q1 2024 down to $2.3 million, a notable decrease from Q1 2023's net loss of $3.5 million.
Business Progress:
BioCardia has completed the enrollment for the CardiAMP Heart Failure trial and anticipates presenting final results for scientific and regulatory submission in Q4 2024.
The company initiated the CardiAMP Heart Failure II trial approved by the FDA and continued progress in other trials for ischemic heart conditions.
BioCardia has established new delivery partnerships with StemCardia and CellProthera, as part of their continuous growth and development strategy.
More details: BioCardia IR
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.